Affimed Announces Proposed Public Offering of Common Stock

- February 13th, 2018

Affimed (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that it has commenced an underwritten public offering of its common shares. The company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of common shares … Continued

Affimed (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that it has commenced an underwritten public offering of its common shares. The company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of common shares sold in connection with the offering. All of the shares in the offering will be sold by Affimed.

As quoted in the press release:

This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies LLC and Wells Fargo Securities, LLC are acting as joint book-running managers.

Click here to read the full press release.

The newest developments in genetics investing

 
Find out what to watch for in the world of genetics

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *